Cardiac monitoring company Cardiologs recently announced a clinical study to monitor COVID-19 patients using smartwatches. The Cardiologs artificial intelligence-based ECG platform is CE marked and FDA cleared for arrhythmia diagnostics and is trained on over 3 million ECG recordings. Now, the company is using that data to support a clinical study to remotely monitor COVID-19 patients during hydroxychloroquine treatment. 

The study will take place at the University Hospital of Marseille in France. The ECG assessment will be performed with Withings Move ECG Watches linked to the Cardiologs AI platform, and the ECG data collected will be used to monitor the QT interval of patients. Prolonged QT intervals are associated with hydroxychloroquine therapy and can lead to severe cardiac arrhythmia.

This past January, Cardiologs raised a $15 million Series A funding round intended to stimulate growth of the company in North America. The funding was led by Alven and joined by Bpifrance, Idinvest Partners, Kurma Diagnostics, ISAI, and the Paris Saclay Seed Fund.